

WEST Search History

DATE: Wednesday, January 30, 2008

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L11	L10 and (@AD<20020902 or @RLAD<20020902 or @PRAD<20020902)	14
<input type="checkbox"/>	L10	parkinson and (statin.ab. or rosuvastatin.ab. or (HMG-CoA).ab.)	29
<input type="checkbox"/>	L9	L7 and parkinson.clm.	8
<input type="checkbox"/>	L8	L7 and parkinson.ab.	2
<input type="checkbox"/>	L7	L6 and (@AD<20020902 or @RLAD<20020902 or @PRAD<20020902)	75
<input type="checkbox"/>	L6	rosuvastatin and parkinson	365
<input type="checkbox"/>	L5	L4 and (@AD<20020902 or @RLAD<20020902 or @PRAD<20020902)	32
<input type="checkbox"/>	L4	L3 and (statin or lovastatin or pravastatin or simvastatin or rosuvastatin)	72
<input type="checkbox"/>	L3	L2 and (Alzheimer or Parkinson)	862
<input type="checkbox"/>	L2	514/278.icls. or 514/278.ccls. or 546/18.icls. or 514/18.ccls.	3712
<input type="checkbox"/>	L1	20050182106.did.	1

END OF SEARCH HISTORY

FILE 'REGISTRY' ENTERED AT 08:41:31 ON 30 JAN 2008

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FAM FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 FAM SAM
L7 STRUCTURE UPLOADED
L8 1 S L7
L9 27 S L8 SSS FULL
L10 STRUCTURE UPLOADED
L11 22 S L10
L12 6 S L10 FAM FULL

FILE 'CAPLUS' ENTERED AT 08:45:43 ON 30 JAN 2008

L13 8 S L9
L14 38 S L12

FILE 'HCAPLUS' ENTERED AT 08:49:05 ON 30 JAN 2008

L15 11725 S (STATIN OR (HMG-COA REDUCTASE) OR ROSUVASTATIN)
L16 181765 S CHOLESTEROL
L17 48829 S ALZHEIMER
L18 25512 S PARKINSON
L19 1 S L13 AND L15
L20 0 S L13 AND L16
L21 6 S L13 AND L17
L22 6 S L13 AND L18

FILE 'HCAPLUS' ENTERED AT 08:49:40 ON 30 JAN 2008

L23 1 S L14 AND L15
L24 0 S L14 AND L16
L25 9 S L14 AND L17
L26 5 S L14 AND L18

FILE 'HCAPLUS' ENTERED AT 08:51:34 ON 30 JAN 2008

L27 14 S L21 OR L25
L28 10 S L22 OR L26

FILE 'HCAPLUS' ENTERED AT 08:52:10 ON 30 JAN 2008

L29 8 S L27 AND (PY<2003 OR AY<2003 OR PRY<2003)
L30 6 S L28 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 08:54:26 ON 30 JAN 2008

L31 8 S L29 OR L30

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 30 JAN 2008

L32 1 S ROSUVASTATIN/CN

FILE 'CAPLUS' ENTERED AT 08:55:16 ON 30 JAN 2008

L33 14 S L18 AND L32
L34 2 S L33 AND (PY<2003 OR AY<2003 OR PRY<2003)
L35 227 S (L15 OR L16) AND L18
L36 84 S L35 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 09:02:50 ON 30 JAN 2008

L37 58 S L15 AND L18
L38 25512 S L18 AND L18
L39 17 S L37 AND (PY<2003 OR AY<2003 OR PRY<2003)
L40 13190 S L38 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HOME' ENTERED AT 08:41:17 ON 30 JAN 2008

=> file registry.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:41:31 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10525783comp2.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

chain bonds :

2-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 8-14 10-11 11-12 11-15
12-13 13-14 13-16 15-16 17-18 17-21 18-19 19-20 20-21

exact/norm bonds :

5-7 6-9 7-8 8-9 8-10 8-14 10-11 11-12 11-15 12-13 13-14 13-16 15-16
17-18 17-21 18-19 19-20 20-21

exact bonds :

2-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:41:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 fam full

FULL SEARCH INITIATED 08:42:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE



100.0% PROCESSED 3 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA FAM FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10525783compl.str



chain nodes :

13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

2-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 5-6 5-10 6-7 7-8 7-11 8-9 9-10 9-12 11-12

exact/norm bonds :

1-2 1-5 2-3 2-13 3-4 4-5 5-6 5-10 6-7 7-8 7-11 8-9 9-10 9-12 11-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS

L4 STRUCTURE UPLOADED

=> s l4

SAMPLE SEARCH INITIATED 08:42:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 360 TO 1080

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 fam sam

SAMPLE SEARCH INITIATED 08:42:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0


PROJECTED ANSWERS: 0 TO 0

L6 0 SEA FAM SAM L4

=> d l4

L4 HAS NO ANSWERS


L4 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10525783comp3.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

chain bonds :

2-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 8-14 10-11 10-15 11-12
12-13 13-14 13-16 15-16 17-18 17-21 18-19 19-20 20-21

exact/norm bonds :

5-7 6-9 7-8 8-9 8-10 8-14 10-11 10-15 11-12 12-13 13-14 13-16 15-16
17-18 17-21 18-19 19-20 20-21

exact bonds :

2-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L7 STRUCTURE UPLOADED

=> s 17

SAMPLE SEARCH INITIATED 08:43:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED

3 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 1 TO 80

L8 1 SEA SSS SAM L7

=> d l8 scan

L8 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine],
5'-(2-bromo-3-furanyl)-, (2'R)-
MF C17 H17 Br N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l8 sss full
FULL SEARCH INITIATED 08:43:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 67 TO ITERATE


100.0% PROCESSED 67 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L9 27 SEA SSS FUL L7

=> d l9 scan

L9 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine],
5'-(5-methyl-3-furanyl)-, dihydrochloride, (2'R)- (9CI)
MF C18 H20 N2 O2 . 2 Cl H

Absolute stereochemistry.




● 2 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L9 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Spiro[1-azabicyclo[2.2.2]octane-3,2' (3'H)-furo[2,3-b]pyridine],
 5'-(3-furanyl)-, (2'R)-
 MF C17 H18 N2 O2
 CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Furanmethanamine, N-methyl-4-[(2'R)-spiro[1-azabicyclo[2.2.2]octane-
 3,2' (3'H)-furo[2,3-b]pyridin]-5'-yl]-
 MF C19 H23 N3 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Spiro[1-azabicyclo[2.2.2]octane-3,2' (3'H)-furo[2,3-b]pyridine],
 5'-[5-(4-morpholinylmethyl)-3-furanyl]-, (2'R)-
 MF C22 H27 N3 O3

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10525783comp4.str



chain nodes :

12

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 13

chain bonds :

2-12

ring bonds :

1-2 1-5 2-3 3-4 4-5 5-6 5-10 6-7 6-13 7-8 8-9 9-10 9-11 11-13

exact/norm bonds :

1-2 1-5 2-3 2-12 3-4 4-5 5-6 5-10 6-7 6-13 7-8 8-9 9-10 9-11 11-13

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:Atom

L10 STRUCTURE UPLOADED

=> s l10

SAMPLE SEARCH INITIATED 08:45:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
PROJECTED ITERATIONS: 360 TO 1080
PROJECTED ANSWERS: 159 TO 721

L11 22 SEA SSS SAM L10

=> s l10 fam full

FULL SEARCH INITIATED 08:45:27 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 138 TO ITERATE

100.0% PROCESSED 138 ITERATIONS
SEARCH TIME: 00.00.01

6 ANSWERS

L12 6 SEA FAM FUL L10

=> d l12 scan


L12 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (3R)-

MF C9 H14 N2 O2

CI COM

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L12 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (3S)-

MF C9 H14 N2 O2

CI COM

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, monohydrochloride
 (9CI)

MF C9 H14 N2 O2 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

320.42

320.63

FILE 'CAPLUS' ENTERED AT 08:45:43 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5

FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 19

L13 8 L9

=> s 112

L14 38 L12

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

321.11

FILE 'STNGUIDE' ENTERED AT 08:45:53 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.30	321.41

FILE 'HCAPLUS' ENTERED AT 08:49:05 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (statin or (HMG-CoA reductase) or rosuvastatin)

```
      5318 STATIN
      12184 HMG
      48545 COA
      95948 REDUCTASE
      7753 HMG-COA REDUCTASE
          (HMG(W) COA(W) REDUCTASE)
      946 ROSUVASTATIN
L15      11725 (STATIN OR (HMG-COA REDUCTASE) OR ROSUVASTATIN)
```

=> s cholesterol

```
L16      181765 CHOLESTEROL
```

=> s Alzheimer

```
L17      48829 ALZHEIMER
```

=> s Parkinson

```
L18      25512 PARKINSON
```

=> s l13 and l15

```
      8 L9
L19      1 L13 AND L15
```

=> s l13 and l16

```
      8 L9
L20      0 L13 AND L16
```

=> s l13 and l17

```
      8 L9
L21      6 L13 AND L17
```

=> s l13 and l18

8 L9
L22 6 L13 AND L18

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	324.10

FILE 'STNGUIDE' ENTERED AT 08:49:14 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	324.16

FILE 'HCAPLUS' ENTERED AT 08:49:40 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l14 and l15

38 L12
L23 1 L14 AND L15

=> s l14 and l16

38 L12
L24 0 L14 AND L16

=> s l14 and l17

38 L12
L25 9 L14 AND L17

=> s l14 and l18

38 L12
L26 5 L14 AND L18

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	326.85

FILE 'STNGUIDE' ENTERED AT 08:49:45 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> d l19 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
TI α 7-Nicotinic receptor agonists and statins in combination for the
treatment of neurodegenerative diseases
AB The invention discloses combinations of α 7-nAChR agonists and
statins, pharmaceutical compns. containing them, and methods of using them for
the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 HCAPLUS <<LOGINID::20080130>>
DN 140:229466
TI α 7-Nicotinic receptor agonists and statins in combination for the
treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256203	A1	20040319	AU 2003-256203	20030901
	EP 1545537	A1	20050629	EP 2003-791540	20030901
	EP 1545537	B1	20070404		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505530	T	20060216	JP 2004-532517	20030901
	AT 358485	T	20070415	AT 2003-791540	20030901
	ES 2283860	T3	20071101	ES 2003-3791540	20030901
	US 2005256146	A1	20051117	US 2005-525783	20050228
	HK 1077193	A1	20070921	HK 2005-109104	20051014
PRAI	SE 2002-2598	A	20020902		

WO 2003-SE1352 W 20030901
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.18	332.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'HCAPLUS' ENTERED AT 08:51:34 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l21 or l25

L27 14 L21 OR L25

=> s l22 or l26

L28 10 L22 OR L26

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	335.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'STNGUIDE' ENTERED AT 08:51:37 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	335.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'HCAPLUS' ENTERED AT 08:52:10 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
 FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l27 and (PY<2003 or AY<2003 or PRY<2003)

```

      22927791 PY<2003
      4475425 AY<2003
      3950531 PRY<2003
L29      8 L27 AND (PY<2003 OR AY<2003 OR PRY<2003)

```

=> s l28 and (PY<2003 or AY<2003 or PRY<2003)

```

      22927791 PY<2003
      4475425 AY<2003
      3950531 PRY<2003
L30      6 L28 AND (PY<2003 OR AY<2003 OR PRY<2003)

```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	338.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'STNGUIDE' ENTERED AT 08:52:17 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.24	338.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.80

FILE 'HCAPLUS' ENTERED AT 08:54:26 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
 FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l29 or l30

L31 8 L29 OR L30

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	2.69	341.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.80

FILE 'STNGUIDE' ENTERED AT 08:54:28 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> d l31 1-8 ti abs bib
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L31 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI α 7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
 AB The invention discloses combinations of α 7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for

the treatment or prophylaxis of neurol. degenerative diseases.

AN 2004:203672 HCAPLUS <<LOGINID::20080130>>
DN 140:229466
TI α 7-Nicotinic receptor agonists and statins in combination for the
treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256203	A1	20040319	AU 2003-256203	20030901 <--
	EP 1545537	A1	20050629	EP 2003-791540	20030901 <--
	EP 1545537	B1	20070404		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505530	T	20060216	JP 2004-532517	20030901 <--
	AT 358485	T	20070415	AT 2003-791540	20030901 <--
	ES 2283860	T3	20071101	ES 2003-3791540	20030901 <--
	US 2005256146	A1	20051117	US 2005-525783	20050228 <--
	HK 1077193	A1	20070921	HK 2005-109104	20051014 <--
PRAI	SE 2002-2598	A	20020902	<--	
	WO 2003-SE1352	W	20030901		
RE.CNT	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L31 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α 7 nicotinic receptor
GI



AB The title compds. (I) [Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substituents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3 substituents, independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO₂R₁, COR₁, cyano, NO₂, (CH₂)_nNR₁R₂; n = 0-2; R₁ and R₂ are independently selected at each occurrence from hydrogen or C1-4 alkyl; R

is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of $\alpha 7$ nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of $\alpha 7$ nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the $\alpha 7$ nicotinic acetylcholine receptor.

AN 2003:837088 HCAPLUS <<LOGINID::20080130>>

DN 139:337962

TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2' (3'H)-furo[2,3-b]pyridine] derivatives as agonists of $\alpha 7$ nicotinic receptor

IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087102	A1	20031023	WO 2003-SE613	20030415 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482311	A1	20031023	CA 2003-2482311	20030415 <--
	AU 2003225456	A1	20031027	AU 2003-225456	20030415 <--
	EP 1499618	A1	20050126	EP 2003-746523	20030415 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009343	A	20050215	BR 2003-9343	20030415 <--
	CN 1662541	A	20050831	CN 2003-813895	20030415 <--
	JP 2005533012	T	20051104	JP 2003-584058	20030415 <--
	ZA 2004008333	A	20060329	ZA 2004-8333	20041014 <--
	MX 2004PA10191	A	20050203	MX 2004-PA10191	20041015 <--
	US 2005176745	A1	20050811	US 2004-511535	20041015 <--
	NO 2004004996	A	20050118	NO 2004-4996	20041117 <--
PRAI	SE 2002-1186	A	20020418	<--	
	SE 2002-3607	A	20021204	<--	
	WO 2003-SE613	W	20030415		

OS MARPAT 139:337962

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2' (3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand

AB Title compound (I) was prepared Thus, (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine, 3-furylboronic acid, (PPh₃)₄Pd, and Na₂CO₃ were heated in H₂O/THF/EtOH at 70° for 24h to give I. I showed acetylcholine α₇ receptor binding with K_i = 0.033 nM.

AN 2003:58809 HCAPLUS <<LOGINID::20080130>>

DN 138:106681

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand

IN Eifion, Phillips

PA USA

SO U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Ser. No. 871,773, abandoned.

CODEN: USXXCO

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003018042	A1	20030123	US 2002-159786	20020531 <--
	US 6569865	B2	20030527		
PRAI	US 2001-367351P	P	20010601	<--	
	US 2001-871773	B1	20010601	<--	

L31 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors

GI



AB The title compound I.2HCl, useful in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders (no biol. data given), was prepared by bromination of (R)-spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine] followed by reacting the resulting 5'-bromo derivative with 3-furylboronic acid in the presence of Pd(PPh₃)₄ and Na₂CO₃ in H₂O/EtOH/THF.

AN 2002:927434 HCAPLUS <<LOGINID::20080130>>

DN 138:14045

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors

IN Phillips, Eifion

PA Astrazeneca Ab, Swed.

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096912	A1	20021205	WO 2002-SE1031	20020529 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2455341	A1	20021205	CA 2002-2455341	20020529 <--
AU 2002303064	A1	20021209	AU 2002-303064	20020529 <--
EP 1397366	A1	20040317	EP 2002-731063	20020529 <--
EP 1397366	B1	20070207		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN 1512995	A	20040714	CN 2002-811049	20020529 <--
BR 2002010075	A	20040817	BR 2002-10075	20020529 <--
JP 2004532877	T	20041028	JP 2003-500091	20020529 <--
NZ 529426	A	20050729	NZ 2002-529426	20020529 <--
AT 353332	T	20070215	AT 2002-731063	20020529 <--
ES 2280538	T3	20070916	ES 2002-2731063	20020529 <--
ZA 2003008779	A	20050211	ZA 2003-8779	20031111 <--
MX 2003PA10996	A	20040227	MX 2003-PA10996	20031128 <--
HK 1063787	A1	20070706	HK 2004-106588	20040901 <--

PRAI US 2001-295206P P 20010601 <--

WO 2002-SE1031 W 20020529 <--

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α -7 nicotinic receptor agonists

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH₂)_m; m = 2 or 3; T = (CH₂)_n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α -7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4 nM. Formulations are given.

AN 2001:752491 HCAPLUS <<LOGINID::20080130>>
Correction of: 2001:676769

DN 135:318499
Correction of: 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α -7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2001066546	A1	20010913	WO 2001-JP1793	20010307 <--
------------------	----	----------	----------------	--------------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-65545 A 20000309 <--

L31 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
analogs as α -7 nicotinic receptor agonists

GI



AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH₂)_m; m = 2 or 3; T = (CH₂)_n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α -7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the K_i value of 4 nM. Formulations are given.

AN 2001:676769 HCAPLUS <<LOGINID::20080130>>

DN 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
analogs as α -7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI WO 2001066546 A1

20010913WO 2001-JP1793 20010307

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRAI JP 2000-65545 20000309

OS MARPAT 135:242223

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Pharmaceutical compositions comprising a positive modulator of a nicotinic
receptor agonist

AB The present invention relates to pharmaceutical compns. comprising a pos.
modulator of a nicotinic receptor agonist, said pos. modulator having the
capacity to increase the efficacy of the said nicotinic receptor agonist.
As an example, effect of nAChR α 7 modulator on agonist activity was
measured by Ca²⁺ flux through nAChR α 7 expressed in HEK-293 cells.
The nicotinic agonist [-]spiro[1-azabicyclo[2,2,2]octane-3,5-oxazolidine]-
2-one was used.

AN 1999:722896 HCAPLUS <<LOGINID::20080130>>

DN 131:317802


TI Pharmaceutical compositions comprising a positive modulator of a nicotinic

receptor agonist
 IN Gurley, David; Lanthorn, Thomas
 PA Astra Aktiebolag, Swed.
 SO PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9956745	A1	19991111	WO 1999-SE700	19990428 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6277870	B1	20010821	US 1998-71826	19980504 <--
	TW 542718	B	20030721	TW 1999-88106373	19990421 <--
	CA 2331070	A1	19991111	CA 1999-2331070	19990428 <--
	AU 9943023	A	19991123	AU 1999-43023	19990428 <--
	AU 770849	B2	20040304		
	BR 9910180	A	20010109	BR 1999-10180	19990428 <--
	EP 1079828	A1	20010307	EP 1999-948542	19990428 <--
	EP 1079828	B1	20030917		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200003244	T2	20010321	TR 2000-3244	19990428 <--
	HU 2001002504	A2	20011128	HU 2001-2504	19990428 <--
	HU 2001002504	A3	20021228		
	EE 200000640	A	20020415	EE 2000-640	19990428 <--
	JP 2002513757	T	20020514	JP 2000-546771	19990428 <--
	AT 249827	T	20031015	AT 1999-948542	19990428 <--
	NZ 507623	A	20040130	NZ 1999-507623	19990428 <--
	RU 2225203	C2	20040310	RU 2000-130209	19990428 <--
	SK 284608	B6	20050701	SK 2000-1570	19990428 <--
	CN 1637149	A	20050713	CN 2004-10088067	19990428 <--
	IN 2000MN00525	A	20050318	IN 2000-MN525	20001020 <--
	MX 2000PA10690	A	20010507	MX 2000-PA10690	20001030 <--
	ZA 2000006133	A	20020130	ZA 2000-6133	20001030 <--
	NO 2000005503	A	20010104	NO 2000-5503	20001101 <--
	US 2001041732	A1	20011115	US 2001-812269	20010320 <--
	US 6861443	B2	20050301		
	HK 1034205	A1	20040121	HK 2001-105008	20010717 <--
PRAI	US 1998-71826	A	19980504	<--	
	WO 1999-SE700	W	19990428	<--	

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of spiroazabicyclic compounds for treatment of psychosis, anxiety, and intellectual impairment.
 GI



AB Title compds. (I; R = H, Me; n = 1, 2), were prepared as agonists of $\alpha 7$ nAChR (nicotinic acetylcholine) receptors (no data). Thus, Me3COAc and then quinuclidine-3-one were added to LDA in THF at -78° and the mixture was allowed to warm to 0° over 1 h to give tert-Bu 2-(3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl)acetate. This was converted to the hydrazide, which in aqueous HCl was treated with aqueous NaNO₂ at

0° to give spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one hydrochloride.

AN 1996:410431 HCAPLUS <<LOGINID::20080130>>

DN 125:86627

TI Preparation of spiroazabicyclic compounds for treatment of psychosis, anxiety, and intellectual impairment.

IN Balestra, Michael; Gordon, John Charles; Griffith, Ronald Conrad; Murray, Robert John

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606098	A1	19960229	WO 1995-SE937	19950822 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2196995	A1	19960229	CA 1995-2196995	19950822 <--
	AU 9534018	A	19960314	AU 1995-34018	19950822 <--
	AU 690735	B2	19980430		
	EP 777671	A1	19970611	EP 1995-930755	19950822 <--
	EP 777671	B1	20000426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	BR 9508751	A	19970812	BR 1995-8751	19950822 <--
	CN 1159808	A	19970917	CN 1995-195518	19950822 <--
	CN 1056846	B	20000927		
	HU 77352	A2	19980330	HU 1997-1965	19950822 <--
	JP 10504561	T	19980506	JP 1996-507995	19950822 <--
	JP 3708962	B2	20051019		
	RU 2148058	C1	20000427	RU 1997-104165	19950822 <--
	AT 192157	T	20000515	AT 1995-930755	19950822 <--
	ES 2145922	T3	20000716	ES 1995-930755	19950822 <--
	PT 777671	T	20000831	PT 1995-930755	19950822 <--
	EE 3399	B1	20010416	EE 1997-39	19950822 <--
	SK 282366	B6	20020107	SK 1997-216	19950822 <--
	CZ 289512	B6	20020213	CZ 1997-392	19950822 <--

PL 183933	B1	20020830	PL 1995-318760	19950822 <--
IN 1995DE01561	A	20050311	IN 1995-DE1561	19950822 <--
IL 115039	A	20010826	IL 1995-115039	19950823 <--
ZA 9507122	A	19960418	ZA 1995-7122	19950824 <--
TW 397837	B	20000711	TW 1995-84108836	19950824 <--
US 5902814	A	19990511	US 1995-525575	19950918 <--
NO 9700800	A	19970221	NO 1997-800	19970221 <--
NO 307707	B1	20000515		
FI 9700762	A	19970224	FI 1997-762	19970224 <--
FI 112868	B1	20040130		
HK 1010370	A1	20000728	HK 1998-110995	19980926 <--
US 6051581	A	20000418	US 1998-188099	19981109 <--
CN 1284505	A	20010221	CN 1999-123574	19991108 <--
CN 1099419	B	20030122		
GR 3033878	T3	20001130	GR 2000-401563	20000704 <--
PRAI GB 1994-17084	A	19940824	<--	
GB 1995-4627	A	19950308	<--	
WO 1995-SE937	W	19950822	<--	
OS MARPAT 125:86627				

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
 DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s rosuvastatin/cn
 L32 1 ROSUVASTATIN/CN

=> fiel caplus
 FIEL IS NOT A RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.61	372.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'CAPLUS' ENTERED AT 08:55:16 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l18 and l32
25512 PARKINSON
843 L32
L33 14 L18 AND L32

=> s l33 and (PY<2003 or AY<2003 or PRY<2003)
22927791 PY<2003
4475425 AY<2003
3950531 PRY<2003
L34 2 L33 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l34 1-2 ti abs bib

L34 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
TI α 7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
AB The invention discloses combinations of α 7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS <<LOGINID::20080130>>
DN 140:229466
TI α 7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003256203	A1	20040319	AU 2003-256203	20030901 <--
EP 1545537	A1	20050629	EP 2003-791540	20030901 <--
EP 1545537	B1	20070404		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006505530	T	20060216	JP 2004-532517	20030901 <--
AT 358485	T	20070415	AT 2003-791540	20030901 <--
ES 2283860	T3	20071101	ES 2003-3791540	20030901 <--
US 2005256146	A1	20051117	US 2005-525783	20050228 <--
HK 1077193	A1	20070921	HK 2005-109104	20051014 <--

PRAI SE 2002-2598 A 20020902 <--
 WO 2003-SE1352 W 20030901

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

TI Medicinal composition for mitigating blood lipid or lowering blood
 homocysteine containing HMG-CoA reductase inhibitors and pyridoxine
 compounds

AB Disclosed is a safe drug for mitigating blood lipid and for reducing the
 amount of blood homocysteine. It is a medicinal composition containing an
 HMG-CoA
 reductase inhibitor and a pyridoxine compound The effect of simvastatin in
 combination with pyridoxine hydrochloride on blood cholesterol in beagle
 dog was examined A tablet containing simvastatin 1.67, pyridoxine
 hydrochloride
 16.7, and other ingredients q.s. to 200 mg was prepared

AN 2004:60308 CAPLUS <<LOGINID::20080130>>
 DN 140:99668

TI Medicinal composition for mitigating blood lipid or lowering blood
 homocysteine containing HMG-CoA reductase inhibitors and pyridoxine
 compounds

IN Kondo, Tatsuhito; Takagi, Ikuo; Nakayama, Masato; Torizumi, Yasuhiro
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

PI	WO 2004006919	A1	20040122	WO 2003-JP8674	20030708 <--
----	---------------	----	----------	----------------	--------------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492781	A1	20040122	CA 2003-2492781	20030708 <--
AU 2003281176	A1	20040202	AU 2003-281176	20030708 <--
CN 1681499	A	20051012	CN 2003-821641	20030708 <--
JP 2004189716	A	20040708	JP 2003-272681	20030710 <--
US 2005182106	A1	20050818	US 2005-31105	20050107 <--

PRAI JP 2002-202121 A 20020711 <--
 JP 2002-343586 A 20021127 <--
 WO 2003-JP8674 W 20030708

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 08:59:45 ON 30 JAN 2008
FILE 'CAPLUS' ENTERED AT 08:59:45 ON 30 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)s

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.78	387.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-8.80

=> s (l15 or l16) and l18
5318 STATIN
12184 HMG
48545 COA
95948 REDUCTASE
7753 HMG-COA REDUCTASE
(HMG(W) COA(W) REDUCTASE)
946 ROSUVASTATIN
181765 CHOLESTEROL
25512 PARKINSON
L35 227 (L15 OR L16) AND L18

=> s l35 and (PY<2003 or AY<2003 or PRY<2003)
22927791 PY<2003
4475425 AY<2003
3950531 PRY<2003
L36 84 L35 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l36 1-20 ti

L36 ANSWER 1 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and compositions using hedgehog polypeptides for treating disorders involving excitotoxicity

L36 ANSWER 2 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

L36 ANSWER 3 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Therapeutic formulations for the treatment of β -amyloid-related diseases

L36 ANSWER 4 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

L36 ANSWER 5 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Prevention and treatment of aging and age-related disorders

L36 ANSWER 6 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

L36 ANSWER 7 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI 22R-Hydroxycholesterol derivatives having a common spirost-5-en-3-ol structure for neuroprotectant pharmaceutical compositions

L36 ANSWER 8 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Composition comprising Xanthoceras sorbifolia extracts, compounds isolated

from same, methods for preparing same, and uses thereof

L36 ANSWER 9 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI compositions facilitating translocation of therapeutic effector across
biol. barrier comprising hydrophobic agent, counter ion, penetrating
peptide, and/or protease inhibitor

L36 ANSWER 10 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Composition comprising Xanthoceras sorbifolia extracts, isolated
compounds, preparation methods, and therapeutic use

L36 ANSWER 11 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of (hetero)aryl substituted pyridones as modulators of LXR

L36 ANSWER 12 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Cell-surface estrogen receptor (ER-X) and related compositions and
therapeutic methods

L36 ANSWER 13 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of substituted indene derivatives as estrogen receptor
modulators

L36 ANSWER 14 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Surface dissolution and/or bulk erosion controlled release pharmaceutical
compositions

L36 ANSWER 15 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI α 7-Nicotinic receptor agonists and statins in combination for the
treatment of neurodegenerative diseases

L36 ANSWER 16 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Oral pharmaceutical formulations containing alkaline agents and binders

L36 ANSWER 17 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Neuronal and optic nerve gene expression patterns in the optic nerve
axotomy model of neuronal degeneration

L36 ANSWER 18 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Use of compounds that activate the sterol regulatory element binding
protein (SREBP) pathway for the treatment of neurodegenerative and
neuroinflammatory disorders

L36 ANSWER 19 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Medicinal composition for mitigating blood lipid or lowering blood
homocysteine containing HMG-CoA reductase
inhibitors and pyridoxine compounds

L36 ANSWER 20 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Assay method for rapid screening of drug candidates for treatment of
amyloidosis and angiopathy involving a biosensor membrane coupled to a
lipid preparation

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

44.14

416.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.60

-8.80

FILE 'STNGUIDE' ENTERED AT 09:00:50 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> d l36 31-84 ti

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L36 ANSWER 31 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Orthomolecular sulfo-adenosylmethionine derivatives with antioxidant properties

L36 ANSWER 32 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment in rats

L36 ANSWER 33 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Markers for the detection of oxidative stress and test kits for diagnosis

L36 ANSWER 34 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and compositions for treating diseases associated with excesses in ACE

L36 ANSWER 35 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

L36 ANSWER 36 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Dopamine agonist formulations for enhanced central nervous system delivery

L36 ANSWER 37 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods using ABCA1 modulators for treating disorders of the nervous and reproductive systems, and methods for identifying agents

L36 ANSWER 38 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and compositions for enhancing pharmaceutical treatments

L36 ANSWER 39 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes

L36 ANSWER 40 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Materials and methods for making improved liposome compositions containing amphipathic peptides and proteins

L36 ANSWER 41 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Inhibition of NF- κ B by triterpene compositions

L36 ANSWER 42 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Nutritional and therapeutical preparations having antioxidant activity

L36 ANSWER 43 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Drug evaluation operating principles

L36 ANSWER 44 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Comparative time-courses of copper-ion-mediated protein and lipid oxidation in low-density lipoprotein

L36 ANSWER 45 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing

amyloidosis-associated diseases

- L36 ANSWER 46 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Hypothalamic digoxin related membrane Na⁺-K⁺ ATPase inhibition and familial basal ganglia calcification
- L36 ANSWER 47 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Does a vegan diet reduce risk for Parkinson's disease?
- L36 ANSWER 48 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Membrane Na⁺ K⁺ ATPase inhibition related dyslipidemia and insulin resistance in neuropsychiatric disorders
- L36 ANSWER 49 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and polymer compositions for gene delivery
- L36 ANSWER 50 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Liposomes containing dopamine entrapped in response to transmembrane ammonium sulfate gradient as carrier system for dopamine delivery into the brain of parkinsonian mice
- L36 ANSWER 51 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Long-term cell culture compositions and genetically modified animals derived therefrom
- L36 ANSWER 52 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Alteration in glycoconjugate metabolism in CNS disorders - role of isoprenoid pathway
- L36 ANSWER 53 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Review: mitochondrial medicine - molecular pathology of defective oxidative phosphorylation
- L36 ANSWER 54 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Time-course of oxidation of lipids in human cerebrospinal fluid in vitro
- L36 ANSWER 55 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Optimization of transdermal iontophoretic delivery of apomorphine for the treatment of Parkinson's disease in vitro
- L36 ANSWER 56 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders
- L36 ANSWER 57 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Serum amyloid A in Alzheimer's disease brain is predominantly localized to myelin sheaths and axonal membrane
- L36 ANSWER 58 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Serum levels of coenzyme Q10 in patients with Parkinson's disease
- L36 ANSWER 59 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Interaction of human substantia nigra neuromelanin with lipids and peptides
- L36 ANSWER 60 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Use of bigenic mouse models and assay systems to identify agents that regulate proliferation and differentiation
- L36 ANSWER 61 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
TI Aging brain and lipid nutrition
- L36 ANSWER 62 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN

TI Changes of erythrocyte and platelet membrane lipid pattern in different subtypes of dementia

L36 ANSWER 63 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death

L36 ANSWER 64 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Biochemical effects of conventional liposomes in mice brain

L36 ANSWER 65 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Effect of long-term parenteral administration of empty and L-Dopa-loaded liposomes on the turnover of dopamine and its metabolites in the striatum of mice with experimental Parkinson's syndrome

L36 ANSWER 66 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Effect of liposomal L-Dopa on Parkinson's syndrome in mice

L36 ANSWER 67 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Potassium, sodium, and cancer: a review

L36 ANSWER 68 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Proanthocyanin for reducing blood lipoprotein and cholesterol

L36 ANSWER 69 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Liposome composition containing selegilin

L36 ANSWER 70 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Oral pharmaceutical controlled-release liquid suspension containing oils and polymers and antioxidants

L36 ANSWER 71 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Compositions and methods for gene therapy to treat disease

L36 ANSWER 72 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Probing membrane bilayer interactions of 1,4-dihydropyridine calcium channel blockers. Implications for aging and Alzheimer's disease

L36 ANSWER 73 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals

L36 ANSWER 74 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease

L36 ANSWER 75 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Increase of serum levels of vitamin E during human aging: Is it a protective factor against death?

L36 ANSWER 76 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease

L36 ANSWER 77 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis

L36 ANSWER 78 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease

L36 ANSWER 79 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Serum coenzyme Q-10 levels in Parkinson's syndrome

L36 ANSWER 80 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Pathobiochemical aspects of Parkinson's disease and dementia of Alzheimer type

L36 ANSWER 81 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Pharmaceutical composition containing ferric ammonium citrate and zinc oxide

L36 ANSWER 82 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Inhibition of tremors in Parkinson's disease with sodium 3,4,5-trimethoxybenzoyl- γ -aminobutyrate administration. Preliminary clinical trial

L36 ANSWER 83 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Polymer-containing composition for hypercholesterolemia

L36 ANSWER 84 OF 84 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Disturbance of the rhythm of the heart during prolonged experimental atherosclerosis and hypertonia in rabbits

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	437.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.80

FILE 'HCAPLUS' ENTERED AT 09:02:50 ON 30 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
 FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l15 and l18

L37 58 L15 AND L18

=> s l18 and l18

L38 25512 L18 AND L18

=> s l37 and (PY<2003 or AY<2003 or PRY<2003)

22927791 PY<2003
4475425 AY<2003
3950531 PRY<2003

L39 17 L37 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l38 and (PY<2003 or AY<2003 or PRY<2003)

22927791 PY<2003
4475425 AY<2003
3950531 PRY<2003

L40 13190 L38 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	439.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.80

FILE 'STNGUIDE' ENTERED AT 09:02:59 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> d l39 1-17 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L39 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Oxidized lipids and uses thereof in the treatment of inflammatory diseases
and disorders
AB The invention provides synthetic oxidized lipids and methods using
oxidized lipids for treating and preventing an inflammation associated with
an endogenous oxidized lipid.
AN 2007:486401 HCAPLUS <<LOGINID::20080130>>
DN 146:475683
TI Oxidized lipids and uses thereof in the treatment of inflammatory diseases
and disorders
IN Harats, Dror; George, Jacob; Halperin, Gideon; Mendel, Itzhak
PA Israel
SO U.S. Pat. Appl. Publ., 87pp., Cont.-in-part of U.S. Ser. No. 567,543.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007099868	A1	20070503	US 2006-528657	20060928
	US 2003225035	A1	20031204	US 2003-445347	20030527 <--
	US 6838452	B2	20050104		
	WO 2004106486	A2	20041209	WO 2004-IL453	20040527
	WO 2004106486	A3	20050106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI US 2003-445347 A1 20030527
 WO 2004-IL453 W 20040527
 US 2006-567543 A2 20060208
 US 2000-252574P P 20001124 <--
 WO 2001-IL101080 A2 20011122 <--
 OS MARPAT 146:475683

L39 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Therapeutic formulations for the treatment of β -amyloid-related diseases

AB The invention discloses methods and pharmaceutical compns. for treating β -amyloid-related diseases, including Alzheimer's disease. The invention e.g. includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid- β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement. Compds. of the invention include e.g. 3-amino-1-propanesulfonic acid and donepezil.

AN 2007:486266 HCAPLUS <<LOGINID::20080130>>

DN 146:455274

TI Therapeutic formulations for the treatment of β -amyloid-related diseases

IN Gervais, Francine; Bellini, Francesco

PA Neurochem (International) Limited, Switz.

SO PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007049098	A2	20070503	WO 2005-IB4199	20050617
	WO 2007049098	A3	20071004		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 2005031651	A1	20050210	US 2004-871537	20040618 <--
	US 2005038117	A1	20050217	US 2004-871365	20040618
	US 7244764	B2	20070717		
	US 2005038000	A1	20050217	US 2004-871512	20040618
	US 2005096385	A1	20050505	US 2004-871514	20040618
	US 2005143462	A1	20050630	US 2004-871543	20040618
	US 7253306	B2	20070807		
	US 2005142191	A1	20050630	US 2004-871549	20040618
	CA 2582385	A1	20051218	CA 2005-2582385	20050617
	EP 1841460	A2	20071010	EP 2005-858504	20050617
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,			

		BA, HR, MK, YU	
PRAI	US	2004-871365	A 20040618
	US	2004-871512	A 20040618
	US	2004-871514	A 20040618
	US	2004-871537	A 20040618
	US	2004-871543	A 20040618
	US	2004-871549	A 20040618
	US	2004-871613	A 20040618
	US	2002-436379P	P 20021224 <--
	US	2003-480906P	P 20030623
	US	2003-480918P	P 20030623
	US	2003-480928P	P 20030623
	US	2003-480984P	P 20030623
	US	2003-482058P	P 20030623
	US	2003-482214P	P 20030623
	US	2003-512017P	P 20031017
	US	2003-512018P	P 20031017
	US	2003-512047P	P 20031017
	US	2003-512116P	P 20031017
	US	2003-512135P	P 20031017
	US	2003-746138	A2 20031224
	WO	2003-CA2011	A 20031224
	WO	2005-IB4199	W 20050617
OS	MARPAT 146:455274		


L39 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Prevention and treatment of aging and age-related disorders
 AB The invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia, and some forms of arthritis and cancer in a subject comprising administration sep., sequentially, or simultaneously of a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol-lowering agents, or biol. or biochem. inhibitors targeting the interleukin-6 signaling pathway. Inhibition of the signal transduction pathway for interleukin 6-mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Said method for prevention and treatment of said disorders is based on inhibition of interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway.

AN 2006:1286190 HCAPLUS <<LOGINID::20080130>>
 DN 146:20347
 TI Prevention and treatment of aging and age-related disorders
 IN Omoigui, Osemwota Sota
 PA USA
 SO U.S. Pat. Appl. Publ., 60pp., Cont.-in-part of U.S. Ser. No. 268,609.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006275294	A1	20061207	US 2006-279239	20060410 <--
	US 2004038874	A1	20040226	US 2002-224743	20020822 <--
	US 2006078531	A1	20060413	US 2004-961037	20041012
	US 2005152905	A1	20050714	US 2005-58371	20050216 <--
	US 2006078532	A1	20060413	US 2005-122030	20050505
	US 2006078533	A1	20060413	US 2005-268609	20051108
PRAI	US 2002-224743	B2	20020822	<--	
	US 2004-961037	A2	20041012		

US 2005-58371	A2	20050216
US 2005-122030	A2	20050505
US 2005-268609	A2	20051108

L39 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of substituted indene derivatives as estrogen receptor
 modulators
 GI



I



II

AB Title compds. I [X = O, NO(H, alkyl, etc.), N-amino, etc.; Y = alkyl, etc.; Z = alkyl, etc.; R3 = H, F, Cl, Br, etc.; R4 = H, OH, F; R5 = H, OH, NH2, Me, etc.; R6 = H, F, Cl, Me, amino, etc.; R7 = H, alkoxy, amino, F, etc.; R10 = H, alk(en/yn)yl, etc.] are prepared For instance, II was prepared in 6 steps from 5-methoxy-1-indanone (no intermediates characterized). Compds. of the invention exhibit binding affinities to the estrogen receptor- α (ER α) in the range of IC50 = 75 - >10000 nM and to the ER β IC50 = 5 - 250 nM. I are useful for the treatment of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, etc.

AN 2004:267344 HCAPLUS <<LOGINID::20080130>>

DN 140:303416

TI Preparation of substituted indene derivatives as estrogen receptor modulators

IN Parker, Dann Leroy; Wilkening, Robert R.; Meng, Dongfang; Ratcliffe, Ronald W.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026887	A2	20040401	WO 2003-US28855	20030915 <--
	WO 2004026887	A3	20050224		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498339	A1	20040401	CA 2003-2498339	20030915 <--
	AU 2003272383	A1	20040408	AU 2003-272383	20030915 <--
	EP 1551820	A2	20050713	EP 2003-754563	20030915 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006508927 T 20060316 JP 2004-537801 20030915 <--
 US 2006041003 A1 20060223 US 2005-528008 20050316 <--
 PRAI US 2002-412093P P 20020919 <--
 WO 2003-US28855 W 20030915
 OS MARPAT 140:303416

L39 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI α 7-Nicotinic receptor agonists and statins in combination for the
 treatment of neurodegenerative diseases
 AB The invention discloses combinations of α 7-nAChR agonists and
 statins, pharmaceutical compns. containing them, and methods of using them for
 the treatment or prophylaxis of neurol. degenerative diseases.
 AN 2004:203672 HCAPLUS <<LOGINID::20080130>>
 DN 140:229466
 TI α 7-Nicotinic receptor agonists and statins in combination for the
 treatment of neurodegenerative diseases
 IN Keith, Richard
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019947	A1	20040311	WO 2003-SE1352	20030901 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003256203	A1	20040319	AU 2003-256203	20030901 <--
EP 1545537	A1	20050629	EP 2003-791540	20030901 <--
EP 1545537	B1	20070404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505530	T	20060216	JP 2004-532517	20030901 <--
AT 358485	T	20070415	AT 2003-791540	20030901 <--
ES 2283860	T3	20071101	ES 2003-3791540	20030901 <--
US 2005256146	A1	20051117	US 2005-525783	20050228 <--
HK 1077193	A1	20070921	HK 2005-109104	20051014 <--
PRAI SE 2002-2598	A	20020902	<--	
WO 2003-SE1352	W	20030901		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Oral pharmaceutical formulations containing alkaline agents and binders
 AB An oral pharmaceutical formulation, e.g., a tablet core, contains an
 uncoated granule of a drug, an optional surfactant, an alkaline agent and a
 combination of a water-soluble binder and a water-insol. binder. The
 controlled release of drugs is achieved by way of the water soluble and water
 insol. binders. The formulation for making granules contained: Eudragit
 NE30D 33.0, Plasdone K30 98.0, sodium lauryl sulfate 6.0, Avicel PH102
 1439.0, felodipine 244.0, and water 1600.0 g. The granules were formed
 into tablets by compressing felodipine granules 160.7, glyceryl
 monostearate 13.5, Crospovidone 79.6, and Avicel PH101 16.2 g.

AN 2004:119765 HCAPLUS <<LOGINID::20080130>>
 DN 140:169654
 TI Oral pharmaceutical formulations containing alkaline agents and binders
 IN Kositprapa, Unchalee
 PA USA
 SO U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 597,206.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004028735	A1	20040212	US 2003-634321	20030804 <--
	US 6096340	A	20000801	US 1997-970489	19971114 <--
	US 6174548	B1	20010116	US 1998-143167	19980828 <--
	US 6077541	A	20000620	US 1999-335575	19990618 <--
	US 6602522	B1	20030805	US 2000-597206	20000620 <--
	US 2003113376	A1	20030619	US 2002-279622	20021023 <--
	US 6780435	B2	20040824		
PRAI	US 1997-970489	A3	19971114	<--	
	US 1998-143167	A2	19980828	<--	
	US 1999-335575	A2	19990618	<--	
	US 2000-597206	A2	20000620	<--	
	US 2000-607293	B1	20000630	<--	

L39 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Medicinal composition for mitigating blood lipid or lowering blood homocysteine containing HMG-CoA reductase inhibitors and pyridoxine compounds
 AB Disclosed is a safe drug for mitigating blood lipid and for reducing the amount of blood homocysteine. It is a medicinal composition containing an HMG-CoA reductase inhibitor and a pyridoxine compound The effect of simvastatin in combination with pyridoxine hydrochloride on blood cholesterol in beagle dog was examined A tablet containing simvastatin 1.67, pyridoxine hydrochloride 16.7, and other ingredients q.s. to 200 mg was prepared

AN 2004:60308 HCAPLUS <<LOGINID::20080130>>
 DN 140:99668
 TI Medicinal composition for mitigating blood lipid or lowering blood homocysteine containing HMG-CoA reductase inhibitors and pyridoxine compounds
 IN Kondo, Tatsuhito; Takagi, Ikuo; Nakayama, Masato; Torizumi, Yasuhiro
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006919	A1	20040122	WO 2003-JP8674	20030708 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492781	A1	20040122	CA 2003-2492781	20030708 <--
	AU 2003281176	A1	20040202	AU 2003-281176	20030708 <--
	CN 1681499	A	20051012	CN 2003-821641	20030708 <--

JP 2004189716	A	20040708	JP 2003-272681	20030710 <--
US 2005182106	A1	20050818	US 2005-31105	20050107 <--
PRAI JP 2002-202121	A	20020711	<--	
JP 2002-343586	A	20021127	<--	
WO 2003-JP8674	W	20030708		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Quinazolinone amide compounds as modulators of nuclear receptors,
 particularly farnesoid X receptor (FXR) and/or orphan nuclear receptors,
 and their preparation, pharmaceutical compositions, and methods of use
 GI



AB Compds., pharmaceutical compns., and methods for modulating the activity of nuclear receptors are provided. In particular, amide-containing quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors. The disclosed compds. include I [$m = 0-4$; $R1 = H$, (un)substituted alk(en/yn)yl, (hetero)aryl, cycloalkyl(alkyl), (hetero)aralkyl, heterocyclyl(alkyl) (preceding groups designated as group A), OH or derivs., NH_2 or derivs.; $R2, R6 =$ (independently) group A, or $R2R6 =$ (un)substituted alkylene; $R4, R5 =$ (independently) group A, OH or derivs., NH_2 or derivs., various acyl, sulfinyl, sulfonyl, or phosphoryl groups, etc.; or $R4R5$ (un)substituted alkylene, alkenylene, alkenylene(oxy/aza)alkenylene; or any of $R2R5, R2R4, R5R6$, or $R4R6$ form 4- to 7-membered, (un)substituted heteroaryl or heterocyclyl group; $R3 =$ (independently) halo, pseudohalo, group A, NH_2 or derivs., OH or derivs., SH or derivs., various acyl, thioacyl, imidoacyl, sulfinyl, or sulfonyl groups; or adjacent $R3R3 =$ (un)substituted alkylene, alkenylene, alkylenedioxy, thioalkylenedioxy, alkylenedithioxy; including stereoisomers, racemates, mixts., and pharmaceutically acceptable derivs.; with one exception compound]. Over 300 specific compds. were prepared and claimed by name. Ten of the most preferred compds. are named. The compds. are useful for treating diseases and disorders selected from: hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, lipodystrophy, hyperglycemia, diabetes mellitus, dyslipidemia, atherosclerosis, gallstone disease, acne vulgaris, acneiform skin conditions, diabetes, Parkinson's disease, cancer, Alzheimer's disease, inflammation, immunol. disorders, lipid disorders, obesity, conditions characterized by a perturbed epidermal barrier function, hyperlipidemia, cholestasis, peripheral occlusive disease, ischemic stroke, obesity, disease states associated with elevated cholesterol levels, conditions of disturbed differentiation or excess proliferation of the epidermis or mucous membrane, and cardiovascular disorders. For instance, Me anthranilate was N-amidated with 2-chloropropionyl chloride (97%), followed by saponification of the ester (97%), and amidation/cyclocondensation of the resultant acid using p-anisidine and PCl_3 (72%), to give

2-(1-chloroethyl)-3-(4-methoxyphenyl)-3H-quinazolin-4-one. This intermediate chloride was aminated with methylamine in THF (99%), and the obtained secondary amine was sulfonylated with 4-tert-butylbenzenesulfonyl chloride and TEA in DCM (92%), to give preferred invention compound II. In an FRET assay for binding to human FXR (ligand-binding domain, fused to glutathione-S-transferase), II had an EC50 of about 300 nM. In an FXR/ECREx7 co-transfection assay using African green monkey kidney cells, II had an efficacy of 190% relative to high control (chenodeoxycholic acid).

AN 2003:737738 HCAPLUS <<LOGINID::20080130>>

DN 139:261313

TI Quinazolinone amide compounds as modulators of nuclear receptors, particularly farnesoid X receptor (FXR) and/or orphan nuclear receptors, and their preparation, pharmaceutical compositions, and methods of use
IN Martin, Richard; Kahl, Jeffery Dean; Flatt, Brenton Todd; Griffith, Ronald
PA X-Ceptor Therapeutics, Inc., USA
SO PCT Int. Appl., 204 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076418	A1	20030918	WO 2003-US6793	20030304 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003228283	A1	20030922	AU 2003-228283	20030304 <--
	EP 1521746	A1	20050413	EP 2003-726031	20030304 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-363132P	P	20020307	<--	
	WO 2003-US6793	W	20030304		

OS MARPAT 139:261313

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods and compositions for enhancing pharmaceutical treatments

AB Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogs, and/or (iii) are inhibitors of tubulin disassembly. Addnl. provided are compns. and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.

AN 2002:778718 HCAPLUS <<LOGINID::20080130>>

DN 137:289046

TI Methods and compositions for enhancing pharmaceutical treatments

IN Newman, Michael J.; Dixon, William Ross

PA USA

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
CODEN: USXXCO


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002147197	A1	20021010	US 2002-104549	20020320 <--
	US 2007203215	A1	20070830	US 2007-627289	20070125 <--
PRAI	US 1999-158322P	P	19991008	<--	
	US 2000-684293	A2	20001006	<--	
	US 2002-104549	B1	20020320	<--	
OS	MARPAT 137:289046				

L39 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Methods of treating or preventing Alzheimer's disease using
 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes
 GI



AB Disclosed are methods for treating or preventing Alzheimer's disease, and other diseases, and/or inhibiting β -secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidinyI compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of preparation are claimed, .apprx.150 example prepsns., translations from the German examples of patent WO 9709311, are included. I inhibit β -secretase with IC50 < 50 μ M; compds. that are effective inhibitors of β -secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyloxy; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO-, -CO-, or C:NOR10- (R10 is carboxyalkyl, alkoxy-carbonylalkyl, alkyl or H), with the bond emanating from an O or S atom joining to a saturated C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenylene, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO; and where m is 0 or 1; with provisos.

AN 2002:754196 HCAPLUS <<LOGINID::20080130>>

DN 137:257677

TI Methods of treating or preventing Alzheimer's disease using
 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes

IN Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 449 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI WO 2002076440 A2 20021003 WO 2002-US9100 20020321 <--
 WO 2002076440 A3 20021128
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002306848 A1 20021008 AU 2002-306848 20020321 <--
 US 2006079533 A1 20060413 US 2004-472868 20040202 <--
 PRAI US 2001-278371P P 20010323 <--
 US 2001-308729P P 20010730 <--
 WO 2002-US9100 W 20020321 <--
 OS MARPAT 137:257677

L39 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Drug evaluation operating principles

AB The present invention relates to methods for determining whether a drug candidate should be advanced from discovery through evaluation to development and marketing. In one embodiment of the present invention, the drug development methods utilize a team decision-making format wherein scientific staff, and regulatory, financial, and marketing personnel may contribute to the evaluation of a new drug compound. In another embodiment of the methods of the present invention, decisions concerning the future of a potential drug may be made at earlier designated timepoints in the evaluation process, and these decisions may be made based on criteria such as preclin. pharmacol. and toxicol. data. In a further embodiment of the present invention, the potential new drug may be assigned a risk characterization, such as a color code, which defines the extent and duration of the evaluation process.

AN 2002:488167 HCAPLUS <<LOGINID::20080130>>

DN 137:57524

TI Drug evaluation operating principles

IN Ernest, Michael; Slate, Doris L.

PA USA

SO U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002081750	A1	20020627	US 2001-956094	20010920 <--
	AU 2002227316	A1	20020708	AU 2002-227316	20011207 <--
PRAI	US 2000-257166P	P	20001222	<--	
	US 2001-956094	A	20010920	<--	
	WO 2001-US47353	W	20011207	<--	

L39 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Hypothalamic digoxin related membrane Na+-K+ ATPase inhibition and familial basal ganglia calcification

AB The isoprenoid pathway produces three key metabolites-digoxin (membrane sodium-potassium ATPase inhibitor and regulator of intracellular calcium-magnesium ratios), dolichol (regulator of N-glycosylation of proteins) and ubiquinone (free radical scavenger). The pathway was assessed in a rare and specific type of familial basal ganglia calcification that is described. The family had a coexistence of basal ganglia calcification (six out of 10 cases), schizophrenia, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, systemic tumors and syndrome X and were all right hemispheric dominant. The isoprenoid pathway was also studied for comparison in right

hemispheric dominant, bihemispheric dominant and left hemispheric dominant individuals. The isoprenoid pathway was upregulated with increased digoxin synthesis in familial basal ganglia calcification. Membrane sodium-potassium ATPase inhibition can lead to an increase in intracellular calcium and calcification of the basal ganglia. There was an increase in tryptophan catabolites and a reduction in tyrosine catabolites. There was also an increase in dolichol and glycoconjugate levels with reduced lysosomal stability in these patients. The ubiquinone levels were low, and free radical levels increased. The cholesterol-phospholipid ratio was increased and the glycoconjugate level of the erythrocyte membrane reduced in this group of patients. No significance difference was noted in family members with and without basal ganglia calcification. These findings were correlated with the pathogenesis of syndrome X, immune mediated diseases, degenerations, tumors and psychiatric disorders noted in the familial basal ganglia calcification described. The biochem. patterns obtained in familial basal ganglia calcification correlated with those in right hemispheric dominance.

AN 2002:86906 HCAPLUS <<LOGINID::20080130>>

DN 137:230547

TI Hypothalamic digoxin related membrane Na⁺-K⁺ ATPase inhibition and familial basal ganglia calcification

AU Kurup, Ravi Kumar; Kurup, Parameswara Achutha

CS Department of Neurology, Medical College Hospital, Trivandrum, Kerala, India

SO Neuroscience Research (Shannon, Ireland) (2002), 42(1), 35-44

CODEN: NERADN; ISSN: 0168-0102

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Membrane Na⁺ K⁺ ATPase inhibition related dyslipidemia and insulin resistance in neuropsychiatric disorders

AB There are several reports in literature implicating cholesterol metabolism in the pathogenesis of neuronal degenerations, oncogenesis, functional neuropsychiatric disorders and multiple sclerosis. Biosynthesis of cholesterol takes place by the isoprenoid pathway, which also produces digoxin, an inhibitor of membrane Na⁺-K⁺ ATPase. Inhibition of this enzyme results in intracellular Mg⁺⁺ deficiency which can influence cholesterol metabolism. Digoxin also influences transport of tryptophan and tyrosine which are precursors of various neurotransmitters. Alterations in digoxin, membrane Na⁺-K⁺ ATPase and also in neurotransmitters have been reported in the disorders mentioned above. In view of this, serum lipid profile, activity of plasma HMG CoA reductase (the major rate limiting step in the isoprenoid pathway), RBC membrane Na⁺-K⁺ ATPase activity, serum Mg⁺⁺ concentration, concentration of digoxin and concentration of

serum neurotransmitters were studied in some neuropsychiatric disorders. The serum serotonin level was increased while that of serum dopamine and noradrenaline was reduced. Serum digoxin levels were high and RBC membrane sodium-potassium ATPase activity and serum magnesium were reduced. There was a reduction in HDL cholesterol and increase in plasma triglycerides (pattern similar to insulin resistance and syndrome X) in most of the disorders studied. The HMG CoA reductase activity was high, the serum total cholesterol was increased while RBC membrane cholesterol was reduced in most of the cases. The significance of increased digoxin with consequent inhibition of membrane Na⁺-K⁺ ATPase in relation to changes in cholesterol metabolism and insulin resistance type of dyslipidemia is discussed in this paper.

AN 2001:683793 HCAPLUS <<LOGINID::20080130>>

DN 136:214833

TI Membrane Na⁺ K⁺ ATPase inhibition related dyslipidemia and insulin

resistance in neuropsychiatric disorders

AU Kumar, A. Ravi; Kurup, P. A.
CS Department of Neurology, Medical College Hospital, Trivandrum, 695 011,
India
SO Indian Journal of Physiology and Pharmacology (2001), 45(3),
296-304
CODEN: IJPPAZ; ISSN: 0019-5499
PB Association of Physiologists and Pharmacologists of India
DT Journal
LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Alteration in glycoconjugate metabolism in CNS disorders - role of
isoprenoid pathway
AB The isoprenoid pathway which is upregulated in neuropsychiatric disorders
produces 2 metabolites which can regulate glycoconjugate metabolism - dolichol
(required for N-glycosylation) and digoxin (endogenous membrane Na-K
ATPase inhibitor producing magnesium depletion). It is known that Mg++
deficiency can influence glycoconjugate metabolism. The results showed an
increase in the concentration of blood serum total glycosaminoglycan (GAG),
glycolipids and carbohydrate component of glycoproteins and a decrease in
the total GAG and carbohydrate component of glycoproteins in the red blood
cell (RBC) membrane suggesting their reduced incorporation into the
membrane. The pattern of change in individual GAG in the serum was
different, however heparan sulfate (HS) and chondroitin sulfate (ChS)
increased in most of the disorders studied. The activity of GAG degrading
enzymes and glycohydrolases showed significant increase in the serum in
all the groups suggesting reduced lysosomal stability consequent to
defective lysosomal membrane formation. The importance of altered
glycoconjugate metabolism in the pathogenesis of multiple sclerosis,
Parkinson's disease, schizophrenia, epilepsy and CNS gliomas is
stressed.

AN 2001:363560 HCAPLUS <<LOGINID::20080130>>
DN 135:342594
TI Alteration in glycoconjugate metabolism in CNS disorders - role of
isoprenoid pathway
AU Kurup, Ravi Kumar Achutha; Devi, Deepa; Augustine, Jyothi; Kurup,
Parameswara Achutha
CS Department of Neurology, Medical College Hospital, Trivandrum, 695011,
India
SO Neuroscience Research Communications (2001), 28(2), 95-106
CODEN: NRCOEE; ISSN: 0893-6609
PB Wiley-Liss, Inc.
DT Journal
LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Review: mitochondrial medicine - molecular pathology of defective
oxidative phosphorylation
AB A review with 322 refs. Different tissues display distinct sensitivities
to defective mitochondrial oxidative phosphorylation (OXPHOS). Tissues
highly dependent on O such as the cardiac muscle, skeletal and smooth
muscle, the central and peripheral nervous system, the kidney, and the
insulin-producing pancreatic β -cell are especially susceptible to defective
OXPHOS. There is evidence that defective OXPHOS plays an important role
in atherogenesis, in the pathogenesis of Alzheimer's disease,
Parkinson's disease, diabetes, and aging. Defective OXPHOS may be
caused by abnormal mitochondrial biosynthesis due to inherited or acquired
mutations in the nuclear (n) or mitochondrial (mt) DNA. For instance, the
presence of a mutation of the mtDNA in the pancreatic β -cell impairs

ATP (ATP) generation and insulin synthesis. The nuclear genome controls mitochondrial biosynthesis, but mtDNA has a much higher mutation rate than nDNA because it lacks histones and is exposed to the radical O species (ROS) generated by the electron transport chain, and the mtDNA repair system is limited. Defective OXPHOS may be caused by insufficient fuel supply, by defective electron transport chain enzymes (Complexes I-IV), lack of the electron carrier coenzyme Q10, lack of oxygen due to ischemia or anemia, or excessive membrane leakage, resulting in insufficient mitochondrial inner membrane potential for ATP synthesis by the FOF1-ATPase. Human tissues can counteract OXPHOS defects by stimulating mitochondrial biosynthesis; however, above a certain threshold the lack of ATP causes cell death. Many agents affect OXPHOS. Several nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit or uncouple OXPHOS and induce the 'topical' phase of gastrointestinal ulcer formation. Uncoupled mitochondria reduce cell viability. The *Helicobacter pylori* induces uncoupling. The uncoupling that opens the membrane pores can activate apoptosis. Cholic acid in exptl. atherogenic diets inhibits Complex IV, cocaine inhibits Complex I, the poliovirus inhibits Complex II, ceramide inhibits Complex III, azide, cyanide, chloroform, and methamphetamine inhibit Complex IV. EtOH abuse and antiviral nucleoside analog therapy inhibit mtDNA replication. By contrast, melatonin stimulates Complexes I and IV and Ginkgo biloba stimulates Complexes I and III. Oral Q10 supplementation is effective in treating cardiomyopathies and in restoring plasma levels reduced by the statin type of cholesterol-lowering drugs.

AN 2001:79969 HCAPLUS <<LOGINID::20080130>>

DN 135:44211

TI Review: mitochondrial medicine - molecular pathology of defective oxidative phosphorylation

AU Fosslie, Egil

CS Department of Pathology, University of Illinois, Chicago, IL, 60612, USA

SO Annals of Clinical and Laboratory Science (2001), 31(1), 25-67

CODEN: ACLSCP; ISSN: 0091-7370

PB Association of Clinical Scientists

DT Journal; General Review

LA English

RE.CNT 322 THERE ARE 322 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders

AB Two substances which are products of the isoprenoid pathway, can participate in lipid peroxidn. 1 Is digoxin, which by inhibiting membrane Na⁺-K⁺ ATPase, causes increase in intracellular Ca²⁺ and depletion of intracellular Mg²⁺, both effects contributing to increase in lipid peroxidn. Ubiquinone, another products of the pathway is a powerful membrane antioxidant and its deficiency can also result in defective electron transport and generation of reactive O species. In view of this and also in the light of some preliminary reports on alteration in lipid peroxidn. in neuropsychiatric disorders, a study was undertaken on the following aspects in some of these disorders (primary generalized epilepsy, schizophrenia, multiple sclerosis, Parkinson's disease and CNS glioma) - (1) concentration of digoxin, ubiquinone, activity of HMG CoA reductase and RBC membrane Na⁺-K⁺ ATPase, (2) activity of enzymes involved in free radical scavenging, (3) parameters of lipid peroxidn., and (4) antioxidant status. The result obtained indicates an increase in the concentration of digoxin and activity of HMG CoA reductase, decrease in ubiquinone levels and in the activity of membrane Na⁺-K⁺ ATPase. There is increased lipid peroxidn. as evidenced from the increase in the concentration of MDA, conjugated dienes, hydroperoxides and NO with decreased antioxidant protection as indicated by decrease in ubiquinone, vit. E and reduced glutathione in schizophrenia, Parkinson's disease and CNS

glioma. The activity of enzymes involved in free radical scavenging like SOD, catalase, glutathione peroxidase and glutathione reductase is decreased in the above diseases. However, there is no evidence of any increase in lipid peroxidn. in epilepsy or MS. The role of increased operation of the isoprenoid pathway as evidenced by alteration in the concentration of digoxin and ubiquinone in the generation of free radicals and protection against them in these disorders is discussed.

AN 2000:450831 HCAPLUS <<LOGINID::20080130>>

DN 133:320518

TI Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders

AU Ravikumar, A.; Arun, P.; Devi, K. V. Deepa; Augustine, J.; Kurup, P. A.

CS Department of Neurology, Medical College, Thiruvananthapuram, 695 011, India

SO Indian Journal of Experimental Biology (2000), 38(5), 438-446

CODEN: IJEBA6; ISSN: 0019-5189

PB National Institute of Science Communication, CSIR

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease

AB The underlying cause of cellular degeneration in the substantia nigra of patients with Parkinson disease has not been clearly established. Metabolic abnormalities may be detected in peripheral non-neuronal cells, such as skin fibroblasts of the patients. A remarkably reduced cholesterol biosynthetic capability was found in fibroblasts from patients with Parkinson disease. The [14C]acetate incorporation into cholesterol was 27.8% of that observed in normal fibroblasts, and the reduced cholesterol synthesis was confirmed by measuring the activity of the rate-limiting enzyme HMGCoA reductase which averaged 6.64 nmol/h/mg protein in the patient fibroblasts compared to 14.70 nmol/h/mg protein in the control fibroblasts. The cholesterol esterification activity, determined as cholesteryl oleate formed from [14C]oleate, of the fibroblasts from Parkinson patients was reduced by 43%. Two hypotheses link the findings with the current exptl. evidences for both increased lipid peroxidn. and defective mitochondrial respiratory chain complex I activity in cells from Parkinson patients. Considering that the decreased cholesterol biosynthesis has been detected in all Parkinson cell lines thus far investigated, this may be a hallmark of the disease.

AN 1993:252610 HCAPLUS <<LOGINID::20080130>>

DN 118:252610

TI Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease

AU Musanti, Roberto; Parati, Eugenio; Lamperti, Elena; Ghiselli, Giancarlo

CS Res. Inst., Farmitalia Carlo Erba, Milan, Italy

SO Biochemical Medicine and Metabolic Biology (1993), 49(2), 133-42

CODEN: BMMBES; ISSN: 0885-4505

DT Journal

LA English